Lonza Group Ag Change in Accounts Receivable 2012-2024 | LZAGY
Lonza Group Ag annual/quarterly change in accounts receivable history and growth rate from 2012 to 2024. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
- Lonza Group Ag change in accounts receivable for the quarter ending December 31, 2024 was $0M, a 0% increase year-over-year.
- Lonza Group Ag change in accounts receivable for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.
- Lonza Group Ag annual change in accounts receivable for 2023 was $-0.039B, a 85.24% decline from 2022.
- Lonza Group Ag annual change in accounts receivable for 2022 was $-0.264B, a 17.34% decline from 2021.
- Lonza Group Ag annual change in accounts receivable for 2021 was $-0.319B, a 79.36% increase from 2020.
| Lonza Group Ag Annual Change in Accounts Receivable (Millions of US $) |
|
|---|---|
| 2023 | $-39 |
| 2022 | $-264 |
| 2021 | $-319 |
| 2020 | $-178 |
| 2019 | $-107 |
| 2017 | $-46 |
| 2016 | $-61 |
| 2015 | $N/A |
| 2014 | $N/A |
| 2013 | $N/A |
| 2012 | $N/A |
| 2011 | $N/A |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $50.537B | $7.468B |
| Lonza Group AG operates as a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The company's Life Science Ingredients segment produces nutrition ingredients for applications in nutrition (food, feed and pharmaceutical application) and chemical intermediates for the agricultural industry. The Microbial Control division focuses on five areas: hygiene, wood protection, water treatment, oil/gas applications, and industrial preservation and comprises products ranging from disinfectants to household cleaning products. The Custom Manufacturing division comprises products used in pharmaceuticals sector. The Bioscience division comprises bioscience products, including cell culture and molecular biology tools for research, tests for microbial detection, and media used in the production of therapeutics. Lonza Group AG is headquartered in Basel, Switzerland. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $232.390B | 27.94 |
| Boston Scientific (BSX) | United States | $154.114B | 38.58 |
| Stryker (SYK) | United States | $145.370B | 30.40 |
| EssilorLuxottica (ESLOY) | France | $128.999B | 0.00 |
| Medtronic (MDT) | Ireland | $107.400B | 15.23 |
| Haleon (HLN) | United Kingdom | $51.375B | 29.26 |
| ResMed (RMD) | United States | $35.781B | 26.88 |
| GE HealthCare Technologies (GEHC) | United States | $32.121B | 15.25 |
| Agilent Technologies (A) | United States | $31.661B | 20.57 |
| Terumo (TRUMY) | Japan | $27.316B | 35.48 |
| Insulet (PODD) | United States | $22.872B | 89.78 |
| Koninklijke Philips (PHG) | Netherlands | $21.440B | 15.41 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.026B | 11.58 |
| Baxter (BAX) | United States | $15.164B | 11.32 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.767B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.032B | 0.00 |
| Demant (WILYY) | Denmark | $8.637B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $5.893B | 20.51 |
| Lantheus Holdings (LNTH) | United States | $5.336B | 13.46 |
| Prestige Consumer Healthcare (PBH) | United States | $4.224B | 18.87 |
| Perrigo (PRGO) | Ireland | $3.672B | 9.31 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Haemonetics (HAE) | United States | $3.304B | 15.05 |
| ICU Medical (ICUI) | United States | $3.213B | 23.69 |
| Envista Holdings (NVST) | United States | $3.068B | 25.49 |
| GN Store Nord (GNNDY) | Denmark | $2.170B | 17.98 |
| QuidelOrtho (QDEL) | United States | $2.005B | 13.79 |
| LeMaitre Vascular (LMAT) | United States | $1.817B | 40.61 |
| AtriCure (ATRC) | United States | $1.683B | 0.00 |
| Acuren (TIC) | United States | $1.297B | 0.00 |
| Neogen (NEOG) | United States | $1.235B | 15.81 |
| AdaptHealth (AHCO) | United States | $1.181B | 11.99 |
| Green Thumb Industries (GTBIF) | United States | $1.143B | 25.71 |
| Kestra Medical Technologies (KMTS) | United States | $1.062B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.996B | 12.74 |
| BioLife Solutions (BLFS) | United States | $0.983B | 0.00 |
| InMode (INMD) | Israel | $0.907B | 9.14 |
| Evolus (EOLS) | United States | $0.643B | 0.00 |
| CeriBell (CBLL) | United States | $0.621B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.549B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.542B | 0.00 |
| Valneva SE (VALN) | France | $0.536B | 0.00 |
| Owens & Minor (OMI) | United States | $0.491B | 4.07 |
| Capricor Therapeutics (CAPR) | United States | $0.466B | 0.00 |
| Surmodics (SRDX) | United States | $0.421B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.410B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.366B | 0.00 |
| SNDL (SNDL) | Canada | $0.334B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.316B | 11.61 |
| Aurora Cannabis (ACB) | Canada | $0.293B | 52.10 |
| Cresco Labs (CRLBF) | United States | $0.289B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.259B | 21.87 |
| Sanara MedTech (SMTI) | United States | $0.259B | 0.00 |
| Cerus (CERS) | United States | $0.252B | 0.00 |
| ZimVie (ZIMV) | United States | $0.251B | 11.40 |
| Verano Holdings (VRNOF) | United States | $0.226B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.224B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.222B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.213B | 0.00 |
| Quanterix (QTRX) | United States | $0.204B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.197B | 0.00 |
| Biote (BTMD) | United States | $0.194B | 5.45 |
| Brainsway (BWAY) | Israel | $0.193B | 51.10 |
| High Tide (HITI) | Canada | $0.186B | 0.00 |
| Omeros (OMER) | United States | $0.180B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.178B | 14.48 |
| Organigram Global (OGI) | Canada | $0.175B | 0.00 |
| Exagen (XGN) | United States | $0.152B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.139B | 17.12 |
| Jin Medical (ZJYL) | China | $0.125B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.103B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.097B | 0.00 |
| Fonar (FONR) | United States | $0.090B | 11.60 |
| MacroGenics (MGNX) | United States | $0.088B | 0.00 |
| Veru (VERU) | United States | $0.085B | 0.00 |
| Agape ATP (ATPC) | $0.080B | 0.00 | |
| Quipt Home Medical (QIPT) | United States | $0.075B | 0.00 |
| InterCure (INCR) | Israel | $0.072B | 0.00 |
| ImmuCell (ICCC) | United States | $0.061B | 0.00 |
| Apyx Medical (APYX) | United States | $0.061B | 0.00 |
| Zynex (ZYXI) | United States | $0.061B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.060B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.054B | 0.00 |
| United Health Products (UEEC) | United States | $0.051B | 0.00 |
| Modular Medical (MODD) | United States | $0.043B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 13.29 |
| Rockwell Medical (RMTI) | United States | $0.034B | 0.00 |
| Nephros (NEPH) | United States | $0.033B | 44.71 |
| Allurion Technologies (ALUR) | United States | $0.020B | 0.00 |
| Safety Shot (SHOT) | United States | $0.020B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.010B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.008B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |